about
Bacillus okhensis sp. nov., a halotolerant and alkalitolerant bacterium from an Indian saltpan.Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow.HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.Tissue engineered humanized bone supports human hematopoiesis in vivo.Pharmacologic stabilization of HIF-1α increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation.Engineering a humanized bone organ model in mice to study bone metastases.Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak.HIF-1α-stabilizing agent FG-4497 rescues human CD34+ cell mobilization in response to G-CSF in immunodeficient mice.Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML.Flow cytometry analysis of cell cycling and proliferation in mouse hematopoietic stem and progenitor cells.Fms-like tyrosine kinase 3 (Flt3) ligand depletes erythroid island macrophages and blocks medullar erythropoiesis in the mouse.Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation.Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs.Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2.Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistanceMobilization with granulocyte colony-stimulating factor blocks medullar erythropoiesis by depleting F4/80(+)VCAM1(+)CD169(+)ER-HR3(+)Ly6G(+) erythroid island macrophages in the mouseControl of Metastases via Myeloid CD39 and NK Cell Effector Function
P50
Q31037254-8EA40A49-FC9E-48DB-BA41-087426A26CF8Q33283654-69AF3AAF-E3EA-4E0E-A9E6-61A79E120768Q35838285-04FBE1CE-2EF6-48FF-BF1C-31268C620E73Q40911412-9AECD7B5-CC8E-45D6-B2D6-975A1FAFCC1CQ43543334-CF45D760-0DAF-4CF5-966E-06E265122F1AQ46410428-A3A2F68C-7551-4837-989A-97AD1ACA999AQ50264554-C3877BFF-26A4-4C0C-80EC-68EC0DC4FD48Q50633873-906107AD-6DC0-4C0B-96D3-F386FA49D6D9Q51636063-F7387357-EEFE-4170-ACE3-277DA3EE9556Q53190879-165114DA-FE8B-4F44-B1F0-BC381C7EBAE0Q53263838-A5A4A3B2-1D17-4662-BA3B-6DD744F82442Q54327926-0F97AC19-9113-4E36-9421-3E6018096FEEQ54415335-B1F947F8-93D9-47AA-92C2-B1C81F9084C4Q64940238-B5DED65E-178E-4028-B258-23B991AAA2A8Q85243285-85C09FD9-5440-44E4-AB8C-06A333823E4CQ87656456-7658C3EC-3FF7-495C-84DB-62B00685E85DQ93011281-48813A80-954C-4A2C-91D7-FA4727F535F1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bianca Nowlan
@ast
Bianca Nowlan
@en
Bianca Nowlan
@es
Bianca Nowlan
@nl
Bianca Nowlan
@sl
type
label
Bianca Nowlan
@ast
Bianca Nowlan
@en
Bianca Nowlan
@es
Bianca Nowlan
@nl
Bianca Nowlan
@sl
prefLabel
Bianca Nowlan
@ast
Bianca Nowlan
@en
Bianca Nowlan
@es
Bianca Nowlan
@nl
Bianca Nowlan
@sl
P106
P21
P31
P496
0000-0002-1049-5284